Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2008
09/04/2008US20080213407 Topical application of L-arginine and menthol to increase penis size
09/04/2008US20080213403 Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
09/04/2008US20080213400 Combinations of Chromium with Antidiabetics for Glucose Metabolism Disorders
09/04/2008US20080213399 Combination Therapies Using Hdac Inhibitors
09/04/2008US20080213398 Modified Azole Compounds as Antifungal and Antibacterial Agents
09/04/2008US20080213397 Nutrient compositions and methods for enhanced effectiveness of the immune system
09/04/2008US20080213396 Treating, preventing anthracycline induced myocardial fibrosis; copper lowering agent is a tetrathiomolybdate, zinc, trientine, d-penicillamine, clioquinoil and tetrathiotungstate
09/04/2008US20080213393 Solid dosage forms; using polyoxyethylene glycol binder; antacids; antidepressants; blood pressure medications; calcium channel blockers; calcium supplements; chemotherapy medications; cold medicines; antihistamines; maintaining or promoting the elimination of feces in the bowel
09/04/2008US20080213385 Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
09/04/2008US20080213378 Atorvastatin; lovastatin; a keto analog of mevinolin; pravastatin; simvastatin; velostatin; fluindostatin; cetyl pyridinium, polymer, biopolymer surface stabilizers; suspensions, gels, aerosols, ointments, creams, controlled release; oral, pulmonary, rectal, opthalmic; improved pharmacokinetic profiles
09/04/2008US20080213376 Medicament that is Intended for Oral Administration, Comprising a Cyclooxygenase-2 Inhibitor, and Preparation Method Thereof
09/04/2008US20080213375 Drying of Drug-Containing Particles
09/04/2008US20080213374 Multi-kinase inhibitor, chemotherapeutics, pain relievers, anti-depressants, anti-inflammatories, ondansetron, nabilone, dronabinol, antibiotics, and antivirals; renal cancer; immune system; viral, bacterial infections; nausea; vomiting; pain; non-renal cancer; fatigue; skin irritation; bone marrow
09/04/2008US20080213371 Nanoparticulate poorly soluble ketoprofen, naproxen in crystalline, semi-crystalline, amorphous form; sugar, a sugar alcohol, a starch, a natural gum, a natural polymer water-soluble, water-dispersible excipient upon contact with saliva
09/04/2008US20080213370 Suspensions of tacrolimus (FK506) anticancer particles with protein or polymer stabilizing agent; shorter administration times; reducing toxicity and hypersensitivity side effects
09/04/2008US20080213368 Method for Stabilizing Anti-Dementia Drug
09/04/2008US20080213366 Therapeutic Compositions
09/04/2008US20080213364 Dissolution profile delivers increased amounts; overcome gastrointestinal side effects associated with high doses; croscarmellose sodium; povidone; microcrystalline cellulose; colloidal silicon dioxide; magnesium stearate; talc; sealing coat surrounding core; enteric coat
09/04/2008US20080213363 Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
09/04/2008US20080213362 Diuretic treatment of edema and congestive heart failure; thiazolidinedione anti-diabetic agent, pioglitazone and rosiglitazone; three layered tablet; not worsen blood sugar levels or glycemic status; dose of about 2 mg or less of torsemide
09/04/2008US20080213361 Coat sodium ibuprofenate crystals with finely divided silica excipient; microcrystalline cellulose; crosslinked polyvinylpyrrolidone binder; mannitol filler; stearic acid disintegrant; poloxamer lubricant; simpler, more cost-efficient; roll compaction, agglomerate, granulate; conventional compression
09/04/2008US20080213356 Sub-lingual tablet, capsule, sachet administration Fluvastatin or Atorvastatin; Dimethicone as stabilizer to inhibit isomerization, elimination, oxidation, recrystallization; binder, diluent, disintegrant, lubricant, glidant; bioavailable; sufficient shelf-life; good pharmacotechnical properties
09/04/2008US20080213351 Compositions and methods for dosing liposomes of certain sizes to treat or prevent disease
09/04/2008US20080213349 Liposome Complexes Containing Pharmaceutical Agents and Methods
09/04/2008US20080213348 Nucleic acid encoding protein effective as hepatocyte growth factor; reducing brain damage caused by cerebral ischemic reperfusion injuries
09/04/2008US20080213347 Novel ligand antagonists of RAR receptors and pharmaceutical/cosmetic applications thereof
09/04/2008US20080213344 Wound dressing and method for controlling severe, life-threatening bleeding
09/04/2008US20080213341 Gastrointestinal tract protection; incorporating as food and/or beverage supplements
09/04/2008US20080213339 Pharmaceutical Composition Containing Indometacin and/or Acemetacin
09/04/2008US20080213338 Implant stent with a retinoid for improved biocompatibility
09/04/2008US20080213334 Polyelectrolyte media for bioactive agent delivery
09/04/2008US20080213333 Introducing biocompatible material that forms scaffold within bone interior and adminstering augmentation agents to elevate blood levels of anabolic agents; promoting osteoblast activity; fracture repair, osteoporosis; kits
09/04/2008US20080213330 Pharmaceutical Compositions Comprising Polyethylene Glycol Having a Molecular Weight of Less Than 600 Daltons
09/04/2008US20080213324 Amphiphilic or lipophilic polar functionalized fullerenes and their uses
09/04/2008US20080213323 Use of active principles which are capable of enhancing the content of ceramides, as protective agent for delicate lips
09/04/2008US20080213319 Using chemorepellents and unimodal fugetaxins as therapeutic tool in treatment of cell proliferative disorders
09/04/2008US20080213314 Combined dna vaccine and biological modifiers for cancer therapy
09/04/2008US20080213308 Imidazoquinoline Compounds
09/04/2008US20080213306 Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
09/04/2008US20080213295 Estrogen receptor polypeptide which induces immune respone; for use in treatment and prevention of cell proliferative disorders; antitumor agents
09/04/2008US20080213286 Composition comprising mastermind domain (MAM) polypeptide for use in treatment of cardiovascular and cell proliferative disorders
09/04/2008US20080213283 Using interleukin-1 inhibitor as therapeutic agent in treatment of spinal cord injury and nervous system disorders; for example, Pralnacasan (VX-740), thalidomide, pentoxifylline, a lazaroid, cyclosporin A
09/04/2008US20080213278 Using taxol and immunosuppressant administration as therapeutic treatment for immune-mediated and/or cell proliferative disorders
09/04/2008US20080213276 G-protein coupled receptor specific immunoglobulin for use in treatment of neurodegenerative, spinal cord, psychological disordrers
09/04/2008US20080213275 Use of mtki 1 for treating or preventing bone cancer
09/04/2008US20080213272 Vegf-related protein
09/04/2008US20080213271 Using dopamine receptor specific immunoglobulin to enhance dopaminergic neurotransmission and treat or prevention nervous system and/or neuropsyciatric disorders
09/04/2008US20080213269 Preventive and/or Treating Agent for Cancer
09/04/2008US20080213258 Method of Predicting and Reducing Risk of Metastasis of Breast Cancer to Lung
09/04/2008US20080213257 Using cytokine antagonist to treat and prevent rheumatoid arthritis and inflammatory bowel diseases
09/04/2008US20080213256 Less Immunogenic Binding Molecules
09/04/2008US20080213252 Methods of treating itch
09/04/2008US20080213248 Methods and Systems for Treating Asthma and Other Respiratory Diseases
09/04/2008US20080213245 Administering glutenase to Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides; gene therapy
09/04/2008US20080213241 Using mixture comprising microbial lipase and/or plant protease for enhancing digestion and treating gastrointestinal disorders
09/04/2008US20080213239 Dietary mixture comprising docosohexaenoic acid, alpha -tocopherol, gamma tocopherol and eicosapentaenoic acid for use in treatment and prevention of inflammatory, rheumatic and cardiovascular disorders
09/04/2008US20080213234 Use of osteopontin for the treatment and/or prevention of neurologic diseases
09/04/2008US20080213221 Providing mammalian cell contacted with agent and adeno-associated virus (AAV), identifying agent that when contacted with mammalian cell enhances AAV transduction after viral binding to membrane of contacted mammalian cell and before second strand synthesis which yields expressible form of viral genome
09/04/2008US20080213219 Methods for treatment and management of macular degeneration using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
09/04/2008US20080213218 Method for treating hepatitis c virus infection in treatment failure patients
09/04/2008US20080213217 (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(S)-phosphinic acid methyl ester; Flaviviruses; bioavailability; pharmacokinetics
09/04/2008US20080213216 Transgenic lymphocytes comprising expression vector coding Fc receptor for use in identifying modulators for prevention and treatment of ifection and immune system disorders
09/04/2008US20080213213 Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
09/04/2008US20080213210 Method to purify poly(vinyl alcohol)
09/04/2008US20080213209 Process for Producing Cross-Linked Material of Polylactic Acid and Cross-Linked Material of Polylactic Acid
09/04/2008US20080213202 Composition For Improving Skin Lipid Barrier Function
09/04/2008US20080213198 Topical use of a UGT inducer-containing composition comprising a dermatologically acceptable carrier to protect and/or enhance the state of the skin/hair and prevent and/or treat imperfections of the skin; flavanoids such as chrysin stimulates isoforms; protective coatings aging/ wrinkling resistance
09/04/2008US20080213194 A cleaning formulation of 0.01-99.9% of rhamnolipid and carrier; antiseptics; deodorants; microbiocides; fungicides; biofilms; biosurfactants; animal cleaning; wound healing agents; personal care; cleaning surfaces of households, food preparation; toys, medical equipment; protective coatings; nontoxic
09/04/2008US20080213186 composition of Tris(8-carboxy-2,2,6,6-(tetra(methoxyethyl)benzo-[1,2-4,5']bis-(1,3)dithiole-4-yl)methyl sodium salt and hyperpolarised 13-pyruvate and pyruvic acid; radioactive C13 isotop; imaging agent for MR imaging; early stage detection of tumor
09/04/2008US20080213184 A method of reducing or preventing a drug-related effect or behavior by inhibiting an N-type calcium channel and is directed toward drugs of abuse, such as, , ethanol, cannabinoids, and opioids; screening conotoxin modulators to effect sedative, hypnotic, ataxia and drug reward and consumption
09/04/2008US20080213179 Differentially Expressed Nucleic Acids in the Blood-Brain Barrier Under Inflammatory Conditions
09/04/2008US20080213178 Using a radiolabeled fatty acid analog such as endo-[18F] fluoro- or [123I]iodo-3,4-cyclopropylheptadecanoic acid localized in tissue of interest, imaging, determining blood flow rate
09/04/2008US20080213177 Nanoparticles Comprising Rna Ligands
09/04/2008US20080213173 Labeled fatty acid analogs; tissue-targeted therapy; tomography; block the catabolic pathway, thus trapping these analogs in a virtually unmodified form in the tissues of interest such as heart, liver, or tumor; endo-vinylic variants of cycloalkyl-substituted heptadecanoic acid for example
09/04/2008US20080213166 Novel Gene Targets and Ligands that Bind Thereto for Treatment and Diagnosis of Colon Carcinomas
09/04/2008US20080213165 Caffeine, partial A2A receptor agonist; caffeine consumption prior to pharmacologic stress testing with an A2A adenosine receptor agonist abbreviate the duration of coronary vasodilation caused by the drug.
09/04/2008DE202008007923U1 Suppositorium Suppository
09/04/2008DE202008006708U1 Kombination von Tocotrienolen mit langkettigen Fettsäuren für Gesunderhaltung, Schmerzlinderung und Entzündungshemmung Combination of tocotrienols with long-chain fatty acids for healthy, relieve pain and inflammation
09/04/2008DE102007059703A1 Oil-in-water-emulsion, useful e.g. in the non-therapeutic treatment of wrinkle, acne and impure skin, comprises a retinoid, a wax component, preferably pentaerythritol ester and/or dipentaerythritol ester, an oil component and water
09/04/2008DE102007010077A1 Use of 1,3-dioxane derivatives to enhance the activity of gamma-aminobutyric acid (GABA) on GABA-A receptors
09/04/2008DE102007009888A1 Use of S-(+)-ketamine for treating depression, which is therapy-refractive depression, preferably depressive episode, relapsing disorder and bipolar affective disorder
09/04/2008DE102007003524A1 Arzneimittel zur Behandlung und/oder Prävention von Arteriosklerose Drugs for the treatment and / or prevention of arteriosclerosis
09/04/2008CA2714601A1 The use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
09/04/2008CA2696053A1 Methods for the treatment of liver diseases
09/04/2008CA2685231A1 Breakthrough pain management
09/04/2008CA2679659A1 Pim kinase inhibitors and methods of their use
09/04/2008CA2679655A1 Hydrochloride salt of an azabicyclo[3.2.1]octane derivative
09/04/2008CA2679629A1 Use of histone deacetylase inhibitors for the treatment of central nervous system metastases
09/04/2008CA2679529A1 Novel dosage form
09/04/2008CA2679525A1 Novel dosage form
09/04/2008CA2679514A1 18f fluoro-benzoyl labelled biologically active compounds as diagnostic imaging agents as well as benzotriazol-1-yloxy-benzoyl, 2,5-dioxo-pyrrolidin-1-yloxy-benzoyl and trimethylammonio-benzoyl precursers
09/04/2008CA2679489A1 Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors
09/04/2008CA2679448A1 Methods and compositions for normalizing meibomian gland secretions
09/04/2008CA2679446A1 New use of glutaminyl cyclase inhibitors
09/04/2008CA2679435A1 Use of inhibitors of the degradation of p27, in particular argyrin and derivatives thereof, for the treatment of proliferative diseases
09/04/2008CA2679429A1 Inhibitors of serine proteases for the treatment of hcv infections
09/04/2008CA2679426A1 Inhibitors of serine proteases
09/04/2008CA2679416A1 Combination therapy, composition and methods for the treatment of cardiovascular disorders
09/04/2008CA2679403A1 Isomers of inositol niacinate and uses thereof
09/04/2008CA2679402A1 Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome